-- BriaCell Therapeutics (BCT.TO) 週四宣布，已將紐約大學朗格尼醫學中心 (NYU Langone Health) 的勞拉和艾薩克·珀爾穆特癌症中心 (Laura and Isaac Perlmutter Cancer Center) 納入其正在進行的 III 期臨床試驗的臨床試驗點。 這項針對晚期乳癌的 III 期臨床試驗 (Bria-ABC) 正在評估該公司的主要候選藥物 Bria-IMT 合併免疫檢查點抑制劑治療晚期轉移性乳癌的療效。 此 III 期臨床試驗將在發生 144 例患者事件（死亡）後進行中期分析，主要終點為總存活期 (OS)。 Bria-IMT 聯合療法已獲得美國食品藥物管理局 (FDA) 的快速通道資格認定。 BriaCell 股票在美國盤前交易中上漲 0.033 美元，至 4.183 美元。
Related Articles
Australia
Max Resource Applies for OTCQB Listing; Shares Down 8.2%
Max Resource (MAX.V) on Thursday said it applied to list its shares on the U.S. OTCQB market.The company's shares will continue to trade on the Toronto Stock Exchange Venture under it current symbol, it said.The company's OTCQB application is subject to OTC Markets' review and approval.The company's shares are eligible for settlement through the Depository Trust Company (DTC), which facilitates the electronic clearing and settlement of publicly traded companies in the United States, the company added."We believe that uplisting on the OTCQB would expand Max's exposure to U.S. investors, increase trading accessibility and liquidity, and support the company's efforts to build a broader international shareholder base as the exploration season advances into full swing," said chief executive Brett Matich.The company's shares were last seen down $0.025 at $0.28 on the TSX Venture Exchange.Price: $0.28, Change: $-0.03, Percent Change: -8.20%
$MAX.V
Australia
Macquarie Downgrades PayPal to Neutral From Outperform, Price Target is $50
PayPal (PYPL) has an average rating of hold and mean price target of $50.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $46.94, Change: $+0.68, Percent Change: +1.46%
$PYPL
Australia
Fortinet Set for Faster Growth on Cyber Risk, AI Upgrades, Wedbush Says
Fortinet (FTNT) is positioned for stronger growth as AI-driven infrastructure needs, rising cyber risks, product upgrades, vendor consolidation, and improving sales momentum support its revenue and billings outlook, Wedbush Securities said Thursday in a report.Q1 billings rose 31% to $2.09 billion, above Wall Street estimates, with strength across security operations and operational technology security, the report said. Revenue climbed 20%, helped by large customers upgrading to higher-performance systems for AI-related workloads, Wedbush said.Operating margins and earnings per share both exceeded expectations on strong execution and cost control, Wedbush said. Fortinet raised its 2026 revenue and billings outlook as cyber threats, data security needs, and cost pressures push customers toward broader cyber platforms, the report said.Wedbush raised its price target on Fortinet stock to $125 from $90 and maintained its outperform rating, citing greater confidence in the company's growth recovery.Price: $110.88, Change: $+20.93, Percent Change: +23.27%
$FTNT